Cooperative Agreement R41CA192419

This Project Grant award for $249,417.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to support the development of a drug product called MT-125 for the treatment of recurrent high-grade glioblastomas (GBM). Glioblastoma is an aggressive and deadly form of brain cancer with a very poor prognosis. The award will fund preclinical studies and a Phase 0/1B dose escalation clinical trial of MT-125, a dual inhibitor of...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research on targeted radioimmunotherapy for glioblastoma, a highly aggressive form of brain cancer. The $432,134 award was granted on June 5, 2025 to the University of Texas MD Anderson Cancer Center. The research aims to develop an innovative treatment approach using IL13RA2, a cell surface receptor expressed on glioblastoma tumors, as a target for delivering cytotoxic radioisotopes....

This $1,296,385 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to accelerate the translation and commercialization of a novel, non-invasive wearable rotating magnetic field therapy device (ONCOMAGNETIC DEVICE or OMTX) targeting the treatment of brain cancers. The device generates spinning oscillating magnetic fields that have demonstrated strong, selective anti-cancer effects on patient-derived glioblastoma (GBM) cells and...

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...

This Project Grant award of $652,751 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to engineer antibody drug conjugates (ADCs) designed to enhance the therapeutic window for treating glioblastoma (GBM) and other central nervous system cancers. The research, conducted by the Mayo Clinic, aims to leverage key findings from prior preclinical studies...

The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...

The National Cancer Institute (NCI) awarded a $919,366 Project Grant to Nuvox Pharma, L.L.C., a small disadvantaged business located in Tucson, Arizona, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The goal of this 2-year project, running from September 2025 to August 2027, is to evaluate liquid biopsy approaches to differentiate pseudoprogression from true disease progression in glioblastoma (GBM) patients treated with chemoradiation and an oxygen...

This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop novel small molecule inhibitors targeting the MBD2 protein for epigenetic therapy of medulloblastoma (MB), a common and aggressive pediatric brain cancer. The $564,045 award supports medicinal chemistry optimization of a lead compound, KCC07, which has shown promise in...